zibotentan inn development code experimental anticancer drug candidate development endothelin receptor zibotentan granted fast track status treatment prostate cancer fda failed phase iii clinical trial prostate trials tolerability zibotentan plus docetaxel zibotentan also studied clinical trials treatment breast cancer colorectal cancer nonsmall cell lung cancer ovarian cancer sclerodermarelated renal bone metastasis heart httpsenwikipediaorgwikizibotentan